{
    "clinical_study": {
        "@rank": "36706", 
        "arm_group": {
            "arm_group_label": "Treatment (MORAb-004)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive anti-endosialin/TEM1 monoclonal antibody MORAb-004 IV on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial studies the side effects and best dose of MORAb-004 in treating young\n      patients with recurrent or refractory solid tumors or lymphoma. Monoclonal antibodies, such\n      as MORAb-004, can block cancer growth in different ways. Some block the ability of cancer to\n      grow and spread. Others find cancer cells and help kill them or carry cancer-killing\n      substances to them"
        }, 
        "brief_title": "MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Adult Nasal Type Extranodal NK/T-cell Lymphoma", 
            "Anaplastic Large Cell Lymphoma", 
            "Angioimmunoblastic T-cell Lymphoma", 
            "Childhood Burkitt Lymphoma", 
            "Childhood Diffuse Large Cell Lymphoma", 
            "Childhood Immunoblastic Large Cell Lymphoma", 
            "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", 
            "Cutaneous B-cell Non-Hodgkin Lymphoma", 
            "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", 
            "Hepatosplenic T-cell Lymphoma", 
            "Intraocular Lymphoma", 
            "Nodal Marginal Zone B-cell Lymphoma", 
            "Noncutaneous Extranodal Lymphoma", 
            "Peripheral T-cell Lymphoma", 
            "Post-transplant Lymphoproliferative Disorder", 
            "Recurrent Adult Burkitt Lymphoma", 
            "Recurrent Adult Diffuse Large Cell Lymphoma", 
            "Recurrent Adult Diffuse Mixed Cell Lymphoma", 
            "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", 
            "Recurrent Adult Grade III Lymphomatoid Granulomatosis", 
            "Recurrent Adult Hodgkin Lymphoma", 
            "Recurrent Adult Immunoblastic Large Cell Lymphoma", 
            "Recurrent Adult Lymphoblastic Lymphoma", 
            "Recurrent Adult T-cell Leukemia/Lymphoma", 
            "Recurrent Childhood Anaplastic Large Cell Lymphoma", 
            "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", 
            "Recurrent Childhood Large Cell Lymphoma", 
            "Recurrent Childhood Lymphoblastic Lymphoma", 
            "Recurrent Childhood Small Noncleaved Cell Lymphoma", 
            "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", 
            "Recurrent Grade 1 Follicular Lymphoma", 
            "Recurrent Grade 2 Follicular Lymphoma", 
            "Recurrent Grade 3 Follicular Lymphoma", 
            "Recurrent Mantle Cell Lymphoma", 
            "Recurrent Marginal Zone Lymphoma", 
            "Recurrent Mycosis Fungoides/Sezary Syndrome", 
            "Recurrent Small Lymphocytic Lymphoma", 
            "Recurrent/Refractory Childhood Hodgkin Lymphoma", 
            "Refractory Hairy Cell Leukemia", 
            "Small Intestine Lymphoma", 
            "Splenic Marginal Zone Lymphoma", 
            "T-cell Large Granular Lymphocyte Leukemia", 
            "Testicular Lymphoma", 
            "Unspecified Adult Solid Tumor, Protocol Specific", 
            "Unspecified Childhood Solid Tumor, Protocol Specific", 
            "Waldenstr\u00f6m Macroglobulinemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Burkitt Lymphoma", 
                "Hodgkin Disease", 
                "Immunoblastic Lymphadenopathy", 
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Hairy Cell", 
                "Leukemia, T-Cell", 
                "Leukemia-Lymphoma, Adult T-Cell", 
                "Lymphoma", 
                "Lymphoma, Follicular", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphomatoid Granulomatosis", 
                "Lymphoproliferative Disorders", 
                "Waldenstrom Macroglobulinemia", 
                "Mycoses", 
                "Mycosis Fungoides", 
                "Sezary Syndrome", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse", 
                "Lymphoma, Large-Cell, Immunoblastic", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Cutaneous", 
                "Lymphoma, T-Cell, Peripheral", 
                "Lymphoma, Large-Cell, Anaplastic", 
                "Lymphoma, B-Cell, Marginal Zone", 
                "Lymphoma, Extranodal NK-T-Cell", 
                "Neoplasms", 
                "Lymphoma, Mantle-Cell", 
                "Leukemia, Large Granular Lymphocytic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose of MORAb-004\n      (anti-endosialin/TEM1 monoclonal antibody MORAb-004) administered as an intravenous infusion\n      every week to children with refractory solid tumors.\n\n      II. To define and describe the toxicities of MORAb-004 administered on this schedule.\n\n      III. To characterize the pharmacokinetics of MORAb-004 in children with refractory cancer.\n\n      IV. To monitor for the development of human anti-human antibody (HAHA) in children receiving\n      MORAb-004.\n\n      SECONDARY OBJECTIVES:\n\n      I. To preliminarily define the antitumor activity of MORAb-004 within the confines of a\n      phase 1 study.\n\n      II. To examine change in plasma tumor endothelial marker-1 (TEM-1) levels as well as\n      circulating proteins involved in the platelet-derived growth factor (PDGF) receptor\n      signaling pathway as potential biomarkers of MORAb-004 activity.\n\n      III. To correlate baseline expression of TEM-1 and proteins involved in the PDGF receptor\n      signaling pathway in tumor samples with clinical parameters including disease response in an\n      exploratory manner.\n\n      OUTLINE: This is a dose escalation study.\n\n      Patients receive anti-endosialin/TEM1 monoclonal antibody MORAb-004 intravenously (IV) on\n      days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 13 courses in the absence\n      of disease progression or unacceptable toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with relapsed or refractory solid tumors or lymphoma, excluding central\n             nervous system (CNS) tumors, are eligible; patients must have had histologic\n             verification of malignancy at original diagnosis or relapse; (patients with primary\n             CNS tumors, known CNS metastases, or a prior history of CNS metastases are not\n             eligible)\n\n          -  Patients must have either measurable or evaluable disease\n\n          -  Patient's current disease state must be one for which there is no known curative\n             therapy or therapy proven to prolong survival with an acceptable quality of life\n\n          -  Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16\n             years of age; Note: patients who are unable to walk because of paralysis, but who are\n             up in a wheelchair, will be considered ambulatory for the purpose of assessing the\n             performance score\n\n          -  Patients must have fully recovered from the acute toxic effects of all prior\n             anti-cancer chemotherapy\n\n          -  At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if\n             prior nitrosourea)\n\n          -  At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta)\n             or 7 days for short-acting growth factor; for agents that have known adverse events\n             occurring beyond 7 days after administration, this period must be extended beyond the\n             time during which adverse events are known to occur; the duration of this interval\n             must be discussed with the study chair\n\n          -  At least 7 days after the last dose of a biologic agent; for agents that have known\n             adverse events occurring beyond 7 days after administration, this period must be\n             extended beyond the time during which adverse events are known to occur; the duration\n             of this interval must be discussed with the study chair\n\n          -  At least 42 days after the completion of any type of immunotherapy, e.g. tumor\n             vaccines\n\n          -  At least 3 half-lives of the antibody after the last dose of a monoclonal antibody\n\n          -  At least 14 days after local palliative radiotherapy (XRT) (small port); at least 150\n             days must have elapsed if prior total-body irradiation (TBI), craniospinal XRT or if\n             >= 50% radiation of pelvis; at least 42 days must have elapsed if other substantial\n             bone marrow (BM) radiation\n\n          -  No evidence of active graft vs. host disease and at least 56 days must have elapsed\n             after transplant or stem cell infusion\n\n          -  For patients with solid tumors without known bone marrow involvement:\n\n          -  Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\n\n          -  Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving\n             platelet transfusions for at least 7 days prior to enrollment)\n\n          -  For patients with known bone marrow metastatic disease:\n\n          -  ANC >= 750/mm^3\n\n          -  Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving\n             platelet transfusions for at least 7 days prior to enrollment)\n\n          -  Patients with known bone marrow metastatic disease will not be evaluable for\n             hematologic toxicity; these patients must not be known to be refractory to red cell\n             or platelet transfusion; at least 5 of every cohort of 6 patients with a solid tumor\n             or lymphoma must be evaluable for hematologic toxicity; if dose-limiting hematologic\n             toxicity is observed, all subsequent patients enrolled must be evaluable for\n             hematologic toxicity\n\n          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) >=\n             70ml/min/1.73 m^2 OR a serum creatinine based on age/gender as follows:\n\n               -  =< 0.6 mg/dL for patients age 1 to < 2 years\n\n               -  =< 0.8 mg/dL for patients age 2 to < 6 years\n\n               -  =< 1 mg/dL for patients age 6 to 10 2 years\n\n               -  =< 1.2 mg/dL for patients age 10 to < 13 years\n\n               -  =< 1.4 mg/dL for female patients age >= 13 years\n\n               -  =< 1.5 mg/dL for male patients age 13 to < 16 years\n\n               -  =< 1.7 mg/dL for male patients age >= 16 years\n\n          -  Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for\n             age\n\n          -  Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 110\n             U/L; for the purpose of this study, the ULN for SGPT is 45 U/L\n\n          -  Serum albumin >= 2 g/dL\n\n          -  Activated partial thromboplastin time (aPTT) and prothrombin time (PT) =< 1.5 x ULN\n\n          -  All patients and/or their parents or legally authorized representatives must sign a\n             written informed consent; assent, when appropriate, will be obtained according to\n             institutional guidelines\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast-feeding women will not be entered on this study; pregnancy tests\n             must be obtained in girls who are post-menarchal; males or females of reproductive\n             potential may not participate unless they have agreed to use an effective\n             contraceptive method\n\n          -  Patients receiving chronic systemic corticosteroids are not eligible\n\n          -  Patients who are currently receiving another investigation drug are not eligible\n\n          -  Patients who are currently receiving other anti-cancer agents are not eligible\n\n          -  Patients who are receiving cyclosporine, tacrolimus or other agents to prevent\n             graft-versus-host disease post bone marrow transplant are not eligible for this trial\n\n          -  Patients who have known human immunodeficiency virus (HIV), viral hepatitis, or an\n             uncontrolled infection are not eligible\n\n          -  Patients with primary CNS tumors are excluded\n\n          -  Patients with prior history of or known metastatic CNS disease involvement are\n             excluded; (Note: CNS imaging for patients without a known history of CNS disease is\n             only required if clinically indicated)\n\n          -  Patients who have had or are planning to have the following invasive procedures are\n             not eligible:\n\n               -  Major surgical procedure, laparoscopic procedure, open biopsy or significant\n                  traumatic injury within 28 days prior to enrollment\n\n               -  Central line placement or subcutaneous port placement is not considered major\n                  surgery but must be placed at least 3 days prior to enrollment for external\n                  lines (e.g. Hickman or Broviac) and at least 7 days prior to enrollment for\n                  subcutaneous port\n\n               -  Core biopsy within 7 days prior to enrollment\n\n               -  Fine needle aspirate within 7 days prior to enrollment\n\n          -  Patients who have received prior solid organ transplantation are not eligible\n\n          -  Patients who in the opinion of the investigator may not be able to comply with the\n             safety monitoring requirements of the study are not eligible\n\n          -  Patients with a history of grade >= 2 allergic reaction to a prior monoclonal\n             antibody therapy are not eligible; patients who have experienced an anaphylactic\n             reaction to a prior monoclonal antibody are not eligible\n\n          -  Patients with history of clinically significant bleeding risk (including evidence of\n             active bleeding: intratumoral hemorrhage by current imaging, or bleeding diathesis;\n             bleeding/coagulation disorder; active fracture; non-healing wound; and active gastric\n             ulcer) are not eligible"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "13 Months"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01748721", 
            "org_study_id": "ADVL1213", 
            "secondary_id": [
                "NCI-2012-01702", 
                "U01CA097452"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (MORAb-004)", 
                "description": "Given IV", 
                "intervention_name": "anti-endosialin/TEM1 monoclonal antibody MORAb-004", 
                "intervention_type": "Biological", 
                "other_name": "MORAb-004"
            }, 
            {
                "arm_group_label": "Treatment (MORAb-004)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }, 
            {
                "arm_group_label": "Treatment (MORAb-004)", 
                "description": "Optional correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 11, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "NA"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35233"
                    }, 
                    "name": "Children's Hospital of Alabama"
                }, 
                "investigator": {
                    "last_name": "Joseph Pressey, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "kduvall@choc.org", 
                    "last_name": "Kathryn Duvall, RN", 
                    "phone": "714-509-8646"
                }, 
                "contact_backup": {
                    "email": "ttempleman@choc.org", 
                    "last_name": "Tina Templeman, RN", 
                    "phone": "714-509-8646"
                }, 
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "Children's Hospital of Orange County"
                }, 
                "investigator": {
                    "last_name": "Ivan Kirov, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Steven DuBois, MD", 
                    "phone": "415-476-3831"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "University of California San Francisco Medical Center - Parnassus"
                }, 
                "investigator": {
                    "last_name": "Steven DuBois, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "REubank@childrensnational.org", 
                    "last_name": "Rachel Eubank", 
                    "phone": "202-476-5533"
                }, 
                "contact_backup": {
                    "email": "ALane@childrensnational.org", 
                    "last_name": "Ashley Lane-Thomas", 
                    "phone": "202-476-2801"
                }, 
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20310"
                    }, 
                    "name": "Children's National Medical Center"
                }, 
                "investigator": {
                    "last_name": "Anne Angiolillo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dana.faircloth@choa.org", 
                    "last_name": "Terrell Faircloth", 
                    "phone": "404-785-3535"
                }, 
                "contact_backup": {
                    "email": "lauren.zahra@choa.org", 
                    "last_name": "Lauren Zahra", 
                    "phone": "404-785-2075"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30307"
                    }, 
                    "name": "Children's Healthcare of Atlanta-Egleston"
                }, 
                "investigator": {
                    "last_name": "Todd Cooper, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "NA"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "18150"
                    }, 
                    "name": "Ann and Robert H. Lurie Children's Hospital of Chicago"
                }, 
                "investigator": {
                    "last_name": "Stewart Goldman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mrsherma@iu.edu", 
                    "last_name": "Marcie Sherman", 
                    "phone": "317-948-0588"
                }, 
                "contact_backup": {
                    "email": "mellee@iu.edu", 
                    "last_name": "Melissa Lee", 
                    "phone": "317-944-4281"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Riley Hospital for Children"
                }, 
                "investigator": {
                    "last_name": "James Croop, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "NA"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "C S Mott Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Rajen J. Mody, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "NA"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55435"
                    }, 
                    "name": "University of Minnesota Cancer Center-Fairview"
                }, 
                "investigator": {
                    "last_name": "Brenda Weigel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "filley_g@kids.wustl.edu", 
                    "last_name": "Gina Filley, RN, CCRP", 
                    "phone": "314-454-4962"
                }, 
                "contact_backup": {
                    "email": "Lluka_b@kids.wustl.edu", 
                    "last_name": "Brunilda Lluka", 
                    "phone": "314-286-1728"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Robert Hayashi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cnp2105@columbia.edu", 
                    "last_name": "Catherine Poulcallec-Gordon", 
                    "phone": "212-305-2478"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Julia Glade Bender, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lori.backus@cchmc.org", 
                    "last_name": "Lori Backus", 
                    "phone": "513-636-2047"
                }, 
                "contact_backup": {
                    "email": "courtney.blank@cchmc.org", 
                    "last_name": "Courtney Blank", 
                    "phone": "513-803-3255"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229"
                    }, 
                    "name": "Cincinnati Children's Hospital Medical Center"
                }, 
                "investigator": {
                    "last_name": "John Perentesis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Robin.Norris@UHhospitals.org", 
                    "last_name": "Robin E. Norris", 
                    "phone": "216-844-3345"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Rainbow Babies & Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Yousif Matloub, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "NA"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health and Science University"
                }, 
                "investigator": {
                    "last_name": "Suman Malempati, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "oncointake@email.chop.edu", 
                    "last_name": "Mia Benson-Smith", 
                    "phone": "267-426-0762"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Children's Hospital of Philadelphia"
                }, 
                "investigator": {
                    "last_name": "Elizabeth Fox, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "angela.krol@chp.edu", 
                    "last_name": "Angela Krol", 
                    "phone": "412-692-8047"
                }, 
                "contact_backup": {
                    "email": "sharon.dibridge@chp.edu", 
                    "last_name": "Sharon Dibridge", 
                    "phone": "412-692-7070"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15224"
                    }, 
                    "name": "Children's Hospital of Pittsburgh of UPMC"
                }, 
                "investigator": {
                    "last_name": "Regina Jakacki, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "roseanne.speights@stjude.org", 
                    "last_name": "Anne Speights", 
                    "phone": "901-595-3561"
                }, 
                "contact_backup": {
                    "email": "jeana.cromer@stjude.org", 
                    "last_name": "Jeana Cromer", 
                    "phone": "901-595-4093"
                }, 
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38105"
                    }, 
                    "name": "Saint Jude Children's Research Hospital"
                }, 
                "investigator": {
                    "last_name": "Wayne Furman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "raklenke@txch.org", 
                    "last_name": "Renee Klenke", 
                    "phone": "832-824-4570"
                }, 
                "contact_backup": {
                    "email": "kamazur@txch.org", 
                    "last_name": "Kate Mazur, PNP", 
                    "phone": "832-824-4266"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Baylor College of Medicine"
                }, 
                "investigator": {
                    "last_name": "Patrick Thompson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Ellamae.Santos@seattlechildrens.org", 
                    "last_name": "Ella Mae Santos", 
                    "phone": "206-884-1591"
                }, 
                "contact_backup": {
                    "email": "Jonathan.Liawgray@seattlechildrens.org", 
                    "last_name": "Jonathan Liaw-Gray", 
                    "phone": "206-884-5184"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98105"
                    }, 
                    "name": "Seattle Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Julie Park, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rrehborg@mcw.edu", 
                    "last_name": "Rebecca Rehborg", 
                    "phone": "414-266-4853"
                }, 
                "contact_backup": {
                    "email": "mshankar@mcw.edu", 
                    "last_name": "Malini Shankar", 
                    "phone": "414-266-2012"
                }, 
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }, 
                    "name": "Midwest Children's Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Michael Kelly, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors", 
        "overall_official": {
            "affiliation": "Children's Oncology Group", 
            "last_name": "Robin Norris", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "MTD, defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicities (DLT) graded according to the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 4 weeks"
            }, 
            {
                "description": "A descriptive summary of all toxicities will be reported.", 
                "measure": "Incidence of toxicities, graded according to NCI CTCAE version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01748721"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Morphotek", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "The Children's Oncology Group (COG)", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Morphotek", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}